FOURIER Analysis Looks at Evolocumab and Risk of MACE Stratified by Obesity

Evolocumab can help attenuate the elevated risk of major adverse cardiovascular events (MACE) that individuals with obesity and atherosclerotic cardiovascular disease (ASCVD) face, according to a prespecified analysis from the FOURIER trial…